Status:
RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Overweight
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health conditi...
Eligibility Criteria
Inclusion
- Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- cardiovascular disease
- Have a history of at least one unsuccessful dietary effort to lose body weight
Exclusion
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
- Have an unstable body weight within 90 days prior to screening
- Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- Have acute or chronic hepatitis or pancreatitis
- Are taking other medications or alternative remedies to manage weight loss
Key Trial Info
Start Date :
May 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06972459
Start Date
May 15 2025
End Date
August 1 2027
Last Update
December 17 2025
Active Locations (80)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, United States, 85375
2
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, United States, 85741
3
Norcal Endocrinology & Internal Medicine
San Ramon, California, United States, 94583
4
Southern California Clinical Research
Santa Ana, California, United States, 92701